Computation | Jotup

Evogene to Present at Cantor Virtual Global Healthcare Conference, September 2021

Retrieved on:

星期二, 九月 14, 2021

Biology, CEO, EST, Health, CPB, Conference, TASE, Castor oil, Therapy, NASDAQ, Computational biology, Investor relations, Computation, Agriculture, AG, Artificial intelligence, Pharmaceutical industry

REHOVOT, Israel, Sept. 14, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational predictive biology company aiming to revolutionize life-science product development acros\s several market segments,announcedtoday that Mr. Ofer Haviv, Evogene's President and CEO, will be interviewed in a "Fireside Chat" at the Cantor Virtual Global Healthcare Conference taking place on September 27-30, 2021.

Key Points:

REHOVOT, Israel, Sept. 14, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational predictive biology company aiming to revolutionize life-science product development acros\s several market segments,announcedtoday that Mr. Ofer Haviv, Evogene's President and CEO, will be interviewed in a "Fireside Chat" at the Cantor Virtual Global Healthcare Conference taking place on September 27-30, 2021.
Mr. Haviv's interview will focus on Evogene's disruptive technologies; its tailor-made engines for product discovery and development and its fields of activity through its main subsidiaries and will take place on Tuesday September 28, 2021, at 10:40 am, EST and will be available through the following webcast link: https://wsw.com/webcast/cantor12/evgn/2086560 .
Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene's Investor Relations team at [email protected] or through the conference's online meeting platform.
Evogene(NASDAQ: EVGN) (TASE: EVGN)is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements.Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabisthrough Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil productionthrough Casterra Ltd. For more information, please visit www.evogene.com .

AnitaB.org Announces Appointment of Dr. Kai Two Feathers Orton as Inaugural Fellow in Residence

Retrieved on:

星期三, 九月 8, 2021

BELMONT, Calif., Sept. 8, 2021 /PRNewswire/ -- AnitaB.org, the global non-profit focused on intersectional gender and pay parity in tech, today announced the appointment of Kai Two Feathers Orton, PhD as the organization's Fellow in Residence, a new position. Effective August, 2, 2021, Dr. Two Feathers Orton will lead AnitaB.org initiatives around strategic partnerships, with the goal of fostering deeper relationships with communities of color and ensuring just futures for all technologists.

Key Points:

BELMONT, Calif., Sept. 8, 2021 /PRNewswire/ -- AnitaB.org , the global non-profit focused on intersectional gender and pay parity in tech, today announced the appointment of Kai Two Feathers Orton, PhD as the organization's Fellow in Residence, a new position.
"I'm thrilled to be named first Fellow In Residence and on Native American Women Equal Pay Day, a significant day to me and so many other women, no less," said Dr. Two Feathers Orton.
Dr. Two Feathers Orton is a First Nations (Innuinait, Cree, Nez Perce, Tlicho) computational scientist, learning technologist, strategic fundraiser, and innovation enthusiast.
In addition to her research, Dr. Two Feathers Orton is a Google Next-Gen Tech Policy Fellow and an active professional member of the American Indian Science and Engineering Society (AISES).

Prevencio’s Novel AI-Driven HART CADhs Blood Test Significantly More Accurate than Troponin for Obstructive Heart Disease

Retrieved on:

星期三, 九月 1, 2021

Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease.

Key Points:

Prevencio, Inc. today announces the presentation of multinational patient data demonstrating its Artificial Intelligence (AI)-driven HART CADhs blood test is more accurate than high sensitivity troponin in determining whether a patient has obstructive heart disease.
Cardiologists from University Heart Center of Hamburg Germany, Massachusetts General Hospital, and Inova Heart and Vascular Institute collaborated to test 924 patients for blood diagnosis of heart disease.
In addition to the HART CADhs blood test for heart disease and imminent risk of heart attack, Prevencio recently launched a second multiprotein blood test, HART CVE, for one-year risk of heart attack, stroke, or cardiac death.
Employing this novel approach, the company has developed seven blood tests that significantly improve diagnosis and risk assessment for a variety of heart and blood vessel-related complications.

FINCAD Announces Women in Finance 2021 Award Winner

Retrieved on:

星期三, 九月 1, 2021

FINCAD, a pioneer in providing pricing, modeling, and risk analytics, today announced the winner of its 2021 Women in Finance Scholarship.

Key Points:

FINCAD, a pioneer in providing pricing, modeling, and risk analytics, today announced the winner of its 2021 Women in Finance Scholarship.
Additionally, about 30 percent of senior officials and managers in the finance and insurance industries were women, according to data from the U.S.
*
Started in 2014, the FINCAD Women in Finance Scholarship is designed to support outstanding women in the financial world pursuing advanced degrees, particularly in the areas of financial asset management, market risk management and derivatives finance within capital markets.
A $20,000 USD award is given to one woman annually to help support her graduate-level studies in Finance.

Evogene to Present at H.C. Wainwright 23rd Annual Global Investment Conference - 2021

Retrieved on:

星期三, 九月 1, 2021

AG, Therapy, Computation, Agriculture, EST, Computational biology, Health, CPB, Biology, NASDAQ, CEO, Conference, Castor oil, Artificial intelligence, Investor relations, TASE, Pharmaceutical industry

REHOVOT, Israel, Sept. 1, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments,announcedtoday that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, 2021, taking place from September 9-15, 2021.

Key Points:

REHOVOT, Israel, Sept. 1, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments,announcedtoday that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, 2021, taking place from September 9-15, 2021.
Mr. Haviv's presentation will focus on Evogene's disruptive technologies, its tailor-made engines for product discovery and development and its fields of activity through its main subsidiaries, and will take place on Thursday September 9, 2021, at 07:30 am, EST.
Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene's Investor Relations team at [email protected] or through the conference's online meeting platform.
Evogene(NASDAQ: EVGN, TASE: EVGN)is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements.Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabisthrough Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil productionthrough Casterra Ltd. For more information, please visit www.evogene.com .

Canonic Announces Pre-Launch of its First Generation Medical Cannabis Products in Israel

Retrieved on:

星期二, 八月 31, 2021

With this, Canonic has completed its end-to-end cannabis value chain in Israel, from seed to product.

Key Points:

With this, Canonic has completed its end-to-end cannabis value chain in Israel, from seed to product.
Canonic is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), developing medical Cannabis products utilizing a Computational Predictive Biology (CPB) platform.
The Company's strategy includes the development of Cannabis varieties in order to commercialize medical Cannabis products independently or through collaborations.
Canonic has exclusive access to Evogene's genomic assets and technology for the development of medical Cannabis products.

Firo Announces Cutting-Edge Privacy Protocol Lelantus Spark

Retrieved on:

星期三, 八月 25, 2021

Firo , a privacy focused cryptocurrency, is unveiling details of its new privacy protocol Lelantus Spark , Firos next major blockchain privacy protocol update that greatly improves the privacy and flexibility of its transactions.

Key Points:

Firo , a privacy focused cryptocurrency, is unveiling details of its new privacy protocol Lelantus Spark , Firos next major blockchain privacy protocol update that greatly improves the privacy and flexibility of its transactions.
Lelantus Spark is Firos latest innovation that furthers its mission of providing clear and consistent transactional privacy.
Firo has always been at the forefront of privacy tech development and we believe Lelantus Spark represents a holistic balance of high anonymity, simplicity and flexibility while remaining true to the spirit of trustlessness in cryptocurrencies.
As a leading technology innovator, Firo designed a simple burn and spend model that strengthens privacy, while making it more broadly accessible.

Photon Enhances Coding Across the Curriculum with New Teaching Kits

Retrieved on:

星期二, 八月 24, 2021

Photon, SEL, Sustainable energy, Problem solving, Student, Computation, Special education, Physics, NSF, Robotics, AI, Awareness, Dartmouth, Massachusetts, Partnership, Early, Artificial intelligence, Teaching kit (museum), Tutoring

MONTVALE, N.J., Aug. 24, 2021 /PRNewswire/ --Eduscape, the leading professional learning organization in the US, is expanding its partnership with Photon to bring Photon Teaching Kits to educators throughout North America.

Key Points:

MONTVALE, N.J., Aug. 24, 2021 /PRNewswire/ --Eduscape, the leading professional learning organization in the US, is expanding its partnership with Photon to bring Photon Teaching Kits to educators throughout North America.
Photon is not just a robot, it is a complete solution for teachers, with no coding experience, to increase student achievement through coding, computer science, and computational thinking.
The Teaching Kits create a learning ecosystem, and content areas include: SEL, Special Education, Early Education, AI Junior, Sustainable Energy, Coding & Robotics, and Physics.
"In the Computational Thinking Counts in Elementary Grades project funded by the NSF, we chose Photon as one of our main technologies.

Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics

Retrieved on:

星期三, 八月 18, 2021

Cerebras Systems , the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics , a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI.

Key Points:

Cerebras Systems , the pioneer in high performance artificial intelligence (AI) compute, and Peptilogics , a biotechnology platform company and an emerging leader in leveraging computation to design novel therapeutics, today announced a collaboration to accelerate the development cycle of peptide therapeutics through AI.
Leveraging the revolutionary Cerebras CS-2 system powered by the worlds fastest AI processor Peptilogics will be able to push the boundaries of innovation in drug design and novel peptide therapeutics.
The design space, or number of possible peptide structures, is vastly larger than could be explored through traditional drug discovery.
Peptilogics joins other life science leaders, including GSK and AstraZeneca, in leveraging Cerebras industry-leading AI technology to advance drug discovery.

Evogene Reports Second Quarter 2021 Financial Results

Retrieved on:

星期三, 八月 11, 2021

REHOVOT, Israel, Aug. 11, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announced today its financial results for the first half and the second quarter of 2021, ended June 30, 2021.

Key Points:

REHOVOT, Israel, Aug. 11, 2021 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across several market segments, announced today its financial results for the first half and the second quarter of 2021, ended June 30, 2021.
Business Development ("BD") expenses: Business Development expenseswere $0.7 million for the second quarter of 2021, in comparison to $0.5 million in the second quarter of 2020.
Operating loss: Operating loss for the second quarter of 2021 was $7.4 million in comparison to $5.2 million in the second quarter of 2020.
Net loss:The net loss for the second quarter of 2021 was $6.9 million in comparison to a net loss of $4.8 million during second quarter of 2020.